Sarepta's Stance on Elevidys - Search News

Order byBest matchMost fresh

News

Sarepta soars

· 9h · on MSN

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food and Drug Administration (FDA) approval to restart shipments of its flagship gene therapy Elevidys in the United States.

Continue reading

Sarepta soars after FDA says some patients can get Elevidys

· 21h · on MSN

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Fierce Pharma1d

FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

8d

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results